The JTB Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HAP1 near-haploid human leukemia cell line, designed to disrupt the JTB gene. This product offers a pooled population of edited cells, enabling loss-of-function studies without clonal isolation. It serves as a versatile tool for investigating mitochondrial apoptosis and cell cycle regulation in a human hematopoietic background.
The HAP1 cell line is a widely used near-haploid human leukemia cell line, originally derived from KBM-7. Its haploid nature facilitates efficient mutagenesis and genetic screening, making it an ideal platform for knockout studies. HAP1 cells maintain key signaling pathways relevant to leukemia and are extensively employed in functional genomics, drug discovery, and cancer biology research.
JTB encodes a mitochondrial protein that functions as a regulator of apoptosis by interacting with BCL2 and BCL2L1, thereby modulating mitochondrial outer membrane permeabilization (MOMP) and the release of cytochrome c. This interaction influences downstream caspase activation, particularly caspase-9, within the intrinsic apoptotic cascade. JTB also participates in cell cycle regulation, linking mitochondrial dynamics to proliferative control. Its association with BAX and other outer membrane proteins positions JTB at a critical node in cell fate decisions.
In the context of HAP1 leukemia cells, JTB knockout disrupts mitochondrial apoptosis signaling, providing a relevant model to study hematopoietic malignancies, including acute myeloid leukemia. Aberrant apoptosis is a hallmark of leukemia, and JTB??s role in MOMP makes it a candidate for understanding drug resistance mechanisms. This polyclonal knockout population enables the analysis of JTB-dependent phenotypes without clonal bias, facilitating robust functional investigations in a leukemia-relevant genetic background.
Researchers can employ these cells in a variety of assays, including Western blotting to assess protein expression changes, co-immunoprecipitation to study JTB?CBCL2 interactions, immunofluorescence to visualize mitochondrial localization, and flow cytometry?Cbased apoptosis assays (e.g., Annexin V staining) and cell cycle analysis. These applications support drug target validation, functional genomics screens, and mechanistic dissection of mitochondrial apoptosis. For further details and technical support, please contact Ascent Research.
